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Abstract
Background: Human immunodeficiency virus (HIV) infection leads to more rapid progression of hepatitis C virus
(HCV)-related liver fibrosis, which could be linked to differences in the severity of liver inflammation among
HIV/HCV co-infected individuals compared to HCV mono-infected individuals.
This study assessed the association of HIV co-infection with pro-inflammatory and pro-fibrogenic cytokines and
chemokines during recent HCV infection.
Methods: Participants from the ATAHC study, a prospective cohort of recent HCV infection, with detectable HCV
RNA at the time of acute HCV detection were included. Concentrations of 27 plasma cytokines and chemokines
were measured by multiplex immunoassays and compared between those with, and without, HIV co-infection.
Results: Out of 117 individuals with recent HCV infection included in analysis, 73 had HCV mono-infection and 44
had HIV/HCV co-infection. Individuals with HIV/HCV co-infection had significantly higher mean levels of eotaxin (1.
79 vs. 1.62 log pg/mL; P < 0.001), monocyte chemotactic protein 1 (MCP-1; 2.10 vs. 1.98 log pg/mL; P < 0.001), and
interferon-gamma inducible protein-10 (IP-10; 3.11 vs. 2.98 log pg/mL; P = 0.013). Linear regression analyses adjusting
for age, alanine transaminase (ALT), HCV RNA levels, and assay run, higher eotaxin levels were independently associated
with HIV/HCV co-infection (adjusted β: 0.12; 95%CI: 0.01, 0.24; P = 0.039). Higher MCP-1 levels were also independently
associated with HIV/HCV co-infection in adjusted analysis (adjusted β: 0.11; 95%CI: 0.03, 0.18; P = 0.009).
Conclusions: During recent HCV, those with HIV/HCV co-infection had a stronger pro-fibrogenic mediator profile
compared to those with HCV mono-infection. These findings may provide a potential explanation for accelerated liver
fibrosis in HIV/HCV co-infection.
Trial registration: Australian Trial in Acute Hepatitis C (ATAHC) study was registered with ClinicalTrials.gov registry on
September 11, 2005. NCT00192569.
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Background
Among people with chronic hepatitis C virus (HCV) in-
fection, co-infection with human immunodeficiency
virus (HIV) leads to accelerated liver fibrosis progression
[1–5]. Several mechanisms have been suggested, includ-
ing increased pro-fibrogenic cytokine expression and se-
cretion, enhanced oxidative stress, increased hepatocyte
apoptosis, and immunosuppression [1, 6–8], although
there is no clear consensus.
One potential explanation for more rapid fibrosis pro-
gression among HIV/HCV co-infected individuals com-
pared to HCV mono-infected individuals could be
differences in the severity of hepatic inflammation, lead-
ing to fibrosis. In the setting of chronic HCV infection,
it has been demonstrated that individuals with HIV/
HCV co-infection have higher levels of a number of pro-
inflammatory cytokines and chemokines [9, 10]. Further,
it has been shown that intrahepatic mRNA levels of in-
flammatory cytokines are higher among people with
HIV/HCV co-infection as compared to HCV mono-
infection [11]. In the setting of acute HCV infection, it
has previously been demonstrated that higher levels of
interferon-gamma inducible protein-10 (IP-10) levels are
observed among people with HIV, compared to those
without HIV infection [12]. However, there are little data
evaluating other cytokine and chemokine levels in
people with, and without, HIV co-infection with recent
HCV infection.
The Australian Trial in Acute Hepatitis C (ATAHC)
was a multicentre, prospective cohort study of the
natural history and treatment of recent (acute and
early chronic) HCV infection [13]. The aim of this
study was to compare cytokine and chemokine levels




In ATAHC, acute or early chronic HCV infection was
defined by an initial positive anti-HCV antibody test
within 6 months of enrolment and either 1) a negative
anti-HCV antibody test within 2 years prior to the initial
positive anti-HCV antibody test or 2) acute clinical
hepatitis within 12 months before the initial positive
anti-HCV antibody result. Acute clinical infection was
defined by symptomatic seroconversion illness or peak
alanine transaminase (ALT) level greater than 400 IU/mL
at or before the time of HCV diagnosis. In the current
study, ATAHC participants with available plasma samples
and HCV RNA detected at the time of acute HCV detec-
tion (screening visit) were included. Cytokines and che-
mokines were measured in screening visit plasma samples
using a multiplex assay (see below).
Measurement of plasma cytokines and chemokines
Three human cytokine multiplex bead array assay kits
utilizing technology licensed by Luminex (Bio-Rad, Gla-
desville, Australia) measured the following cytokines and
chemokines: interleukin-1b (IL-1b), IL-4, IL-6, IL-10, IL-
17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33,
interferon-gamma (IFN-g), soluble CD40 ligand (sCD40L),
tumor necrosis factor alpha (TNF-a), (with Bio-Plex hu-
man TH17 15-plex), IL-2, IL-8, eotaxin-1 (or CCL11),
IFN-g, interferon-gamma inducible protein-10 (IP-10, or
CXCL10), monocyte chemotactic protein 1 (MCP-1, or
CCL2), macrophages inflammatory proteins 1 alpha (MIP-
1a, or CCL3), MIP-1ß (or CCL4), RANTES (regulated
upon activation normal T-cell expressed, and presumably
secreted; or CCL5) (with Bio-Plex human cytokine Group I
9-plex) and IL-18, TNF-ß, TNF-related apoptosis-inducing
ligand (TRAIL, or TNFSF10) (with Bio-Plex human cyto-
kine Group II 3-plex).
The protocol was performed as per the manufac-
turer’s instructions and previously described [14, 15].
Samples were centrifuged at 10,000 x g for 10 min at
4 °C to remove platelets and precipitates, after which
the supernatants were diluted four times with assay
diluents. The assay was performed using all the assay
components provided in a 96-well filter plate. The
raw data was analysed using the Bio-Plex Manager
software, v6.1 (Bio-Rad) [16].
Statistical analysis
Log10 transformed values of cytokines levels (log10
pg/mL) were used in analysis given the distribution of
the actual values were not normal. The mean of
plasma cytokine levels were compared between indi-
viduals with and without HIV co-infection (Student T
test). If the plasma cytokine level was below the level
of detection, the midpoint between zero and the low-
est level of reliable detection was imputed (Additional
file 1: Table S1). Plasma levels of four cytokines (IL-23,
IFN-g, TNF-b, and MIP-1a) were undetectable in ≥20 %
of individuals, for which proportion of individuals with
undetectable cytokine level was compared between indi-
viduals with, and without, HIV co-infection (Chi-squared
test).
Overall, 27 comparisons of plasma cytokines levels
were conducted between two groups of individuals with,
and without, HIV co-infection. Whether adjustments are
needed for multiple comparisons is a matter of contro-
versy given that multiple comparison testing might in-
flate type 1 error while adjustments for multiple
comparisons inflate type 2 error [17–20]. To account for
multiple comparisons, a moderately conservative signifi-
cance level (alpha = 0.01) was used. In a sensitivity ana-
lysis, using Bonferroni correction for multiple
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comparisons, an alpha = 0.05/27 = 0.002 was also used,
but the findings were similar.
Two cytokines (i.e., MCP-1 and eotaxin) which had
significantly different means between individuals
with, and without, HIV co-infection were included in
linear regression analysis. Linear regression models
were fitted to assess the association of HIV co-
infection with each plasma cytokine levels (log pg/mL). In
the adjusted models, the association of these two cyto-
kines and HIV co-infection was adjusted for potential con-
founders including age, ALT levels, and HCV RNA level
at the time of acute HCV detection. Potential confounders
were the variables associated with either HIV status or
plasma cytokine levels in this study. To account for poten-
tial unmeasured confounders introduced by different assay
runs and sample set, the models were also adjusted for
assay set. All analyses were performed using Stata v12.0
(College Station, TX, United States).
Results
Participant characteristics
A total of 117 individuals with recent HCV infection
were included in the study, including 44 (38 %) with and
73 without (62 %) HIV co-infection. Background charac-
teristics of the study population are summarized in
Table 1. All individuals with HIV co-infection were male.
Compared to individuals without HIV, those with HIV
co-infection were significantly older, had a higher ALT
level and had a greater proportion with high HCV RNA
levels (≥400,000 IU/mL) at the time of recent HCV
detection (Table 1). Two participants had HBV co-
infection (positive HBsAg), both with no HIV co-
infection.
Among 44 individuals with HIV co-infection, 24
(55 %) had HIV viral suppression (≤50 IU/ml) at the
time of recent HCV detection. Among those with no
HIV viral suppression, the median HIV RNA levels at
the time of recent HCV detection was 4400 IU/mL (in-
ter quartile range: 400, 33467). CD4 count at the time of
acute HCV detection was ≥500 cells/μL in 28 (64 %) in-
dividuals, and 200–499 cells/μL in 14 (32 %) individuals
(not available in two individuals). Thirty-three individ-
uals (75 %) were on antiretroviral therapy at the time of
acute HCV detection, among whom, 18 (55 %) had HIV
viral suppression.
During the follow-up, ten individuals (9 %) cleared
HCV spontaneously, while 107 individuals (91 %) either
progressed to chronic infection, or received treatment.
Distribution of cytokines levels by HIV status
The distribution of cytokine levels in individuals with,
and without, HIV co-infection is summarized in Table 2.
Individuals with HIV co-infection had significantly
higher mean plasma levels of MCP-1 and eotaxin
compared to those without HIV (P < 0.001; Fig. 1a and b).
IP-10 also had higher mean plasma levels in those with
HIV co-infection compared to those without HIV co-
infection (P = 0.013; Fig. 1c).
In unadjusted linear regression analysis, HIV co-
infection was significantly associated with higher
plasma MCP-1 levels [log pg/mL; β (estimated mean
difference): 0.13; 95 % CI: 0.06, 0.19; Table 3]. In the
adjusted model, HIV co-infection remained highly
significantly associated with higher MCP-1 levels
(log pg/mL; adjusted β: 0.11; 95 % CI: 0.03, 0.18;
Table 3).
Table 1 Baseline characteristics of ATAHC participants with
detectable HCV RNA at the time of acute HCV detection,











n (%) a n (%) a n (%) a
Sex <0.001
Male 88 (75) 44 (60) 44 (100)
Female 29 (25) 29 (40) 0 (0)
Mean age, year (SD) 34 (10) 31 (9) 41 (8) <0.001
Symptomatic acute HCV 0.825
No 68 (58) 43 (59) 25 (57)
Yes 49 (42) 30 (41) 19 (43)




2.1 (0.5) 2.4 (0.5) 0.006
Estimated duration of
infection at acute HCV
detection
0.236
<26 weeks 69 (59) 40 (55) 29 (66)




TT/CT 56 (48) 37 (51) 19 (43)
CC 59 (50) 37 (49) 23 (53)
Unknown 2 (2) 0 (0) 2 (4)
HCV RNA level at acute
HCV detection
0.031
<400,000 IU/mL 78 (67) 54 (74) 24 (55)
≥400,000 IU/mL 39 (33) 19 (26) 20 (45)
HCV genotype 0.682
Genotype 1 67 (57) 41 (56) 26 (59)
Genotype 3 40 (34) 27 (37) 13 (29)
Other genotypesb 8 (7) 4 (5) 4 (9)
Unknown genotype 2 (2) 1 (1) 1 (2)
Abbreviation: SD standard deviation
aPercentages indicate column percentages
bIncluding genotype 2 (n = 6), genotype 4 (n = 1) and mixed genotype (n = 1)
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In unadjusted linear regression analysis, HIV co-
infection was also significantly associated with higher
plasma eotaxin levels (log pg/mL; β: 0.17; 95 % CI: 0.07,
0.28; Table 4). In the adjusted model, HIV co-infection
remained significantly associated with higher eotaxin
levels (log pg/mL; adjusted β: 0.12; 95 % CI: 0.01, 0.24;
Table 4).
Given that there were no females with HIV co-
infection, models were not adjusted for sex. However, in
a sensitivity analysis restricting the study population to
males, a similar trend was observed with respect to the
relationship between HIV infection and both MCP-1
(Additional file 1: Table S2) and eotaxin (Additional file 1:
Table S3).
Among individuals with HIV co-infection, the mean
plasma levels of MCP-1 and exotoxin among individuals
with CD4 count ≥500 cells/μL were 2.12 log pg/mL
Table 2 Plasma cytokine and chemokine levels among ATAHC
participants with detectable HCV RNA at the time of acute HCV
detection, stratified by HIV





IL-1 betaa 0.77 (0.77) 0.56 (0.59) 0.197
IL-2a 1.11 (0.12) 1.09 (0.13) 0.427
IL-4a 2.16 (0.25) 2.13 (0.28) 0.589
IL-6a 1.60 (0.63) 1.60 (0.64) 0.977
IL-8a 1.71 (0.54) 1.71 (0.48) 0.994
IL-10a 2.16 (0.66) 1.94 (0.72) 0.100
IL-17Aa 2.05 (0.53) 1.89 (0.70) 0.212
IL-17Fa 2.34 (0.49) 2.17 (0.56) 0.088
IL-18a 2.44 (0.29) 2.52 (0.25) 0.171
IL-21a 3.13 (0.55) 3.07 (0.56) 0.566
IL-22a 1.73 (0.68) 1.81 (0.53) 0.458
IL-23b 16 (22) 14 (32) 0.252
IL-25a 1.46 (0.72) 1.32 (0.94) 0.415
IL-31a 2.58 (0.51) 2.53 (0.61) 0.641
IL-33a 3.49 (0.26) 3.41 (0.29) 0.245
IFN-gammaa 2.62 (0.36) 2.68 (0.39) 0.417
IFN-gamma2b 57 (79) 38 (86) 0.329
TNF-alphaa 1.30 (0.47) 1.27 (0.47) 0.776
TNF-betab 68 (93) 43 (98) 0.407
TRAILa 2.07 (0.18) 2.12 (0.21) 0.119
sCD40La 2.89 (0.26) 2.90 (0.25) 0.865
CXCL10 (IP-10) a 2.98 (0.24) 3.11 (0.28) 0.013
CCL2 (MCP-1) a 1.98 (0.17) 2.10 (0.19) <0.001
CCL3 (MIP-1a) b 36 (49) 16 (36) 0.172
CCL4 (MIP-1b) a 2.62 (0.24) 2.70 (0.32) 0.158
CCL5 (RANTES) a 3.78 (1.66) 3.94 (1.56) 0.606
CCL11 (eotaxin) a 1.62 (0.30) 1.79 (0.21) <0.001
a Presented as mean plasma level (standard deviation); log10 pg/mL
b Presented as the number with undetectable plasma level (%)
Fig. 1 Distribution of MCP-1 (a), eotaxin (b) and IP-10 (c) plasma
levels among ATAHC participants with detected HCV RNA at acute
HCV detection, by HIV status. Horizontal lines represent the mean
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[standard deviation (SD): 0.21] and 1.78 log pg/mL (SD:
0.19), respectively, which were comparable to 2.09 log
pg/mL (SD: 0.18) and 1.83 log pg/mL (SD: 0.27), re-
spectively among those with CD4 count 200–499 cells/
μL (P = 0.627 and P = 0.524, respectively).
In another analysis, the association of estimated of
duration of HCV infection at the time of HCV detection
with plasma cytokines levels were assessed (Additional
file 1: Table S4). The mean plasma levels of IL-2 was sig-
nificantly higher in individuals with an estimated of dur-
ation of HCV infection ≥26 weeks (1.07 log pg/mL; SD:
0.08) compared to those with an estimated of duration
of HCV infection <26 weeks (1.15 log pg/mL; SD: 0.15;
P = 0.001).
Discussion
This study assessed the association of plasma cytokine
and chemokine levels with HIV co-infection among indi-
viduals with recent HCV infection. HIV/HCV co-
infection was independently associated with higher
plasma levels of two pro-inflammatory and pro-
fibrogenic chemokines, MCP-1 and eotaxin. Increased
plasma levels of MCP-1 and eotaxin in HIV/HCV co-
infection might reflect increased hepatic expression of
these cytokines and a subsequent chronic pro-
inflammatory response [21, 22].
Individuals with HIV/HCV co-infection and recent
HCV infection in this study had significantly higher
MCP-1 plasma levels compared to those with HCV
mono-infection, which is consistent with findings in the
setting of chronic HCV infection [9]. Similar findings in
the setting of recent HCV infection are important and
suggest that elevated levels of MCP-1 in HIV/HCV co-
infected individuals occur early following HCV infection.
A previous study has shown that MCP-1 plasma levels
were elevated in HIV infection and correlated with HIV
RNA levels [23]. However, MCP-1 plasma levels in the
current study were comparable between HIV co-infected
individuals with and without HIV viral suppression.
C-C chemokine receptor 2 (CCR2) and its main ligand
MCP-1 (CCL2) have major roles in promoting the accu-
mulation and activation of monocyte-macrophages in
Table 3 Unadjusted and adjusted models assessing the association of HIV co-infection with plasma MCP-1 levels (log10 pg/mL) in
ATAHC
Unadjusted model Adjusted modela
Estimated mean differenceb (95 % CI) P Estimated mean differenceb (95 % CI) P
HIV co-infection
Negative Reference Reference
Positive 0.13 (0.06, 0.19) <0.001 0.11 (0.03, 0.18) 0.009
Age, 10 years 0.04 (0.00, 0.07) 0.024 0.01 (−0.03, 0.05) 0.575
Symptomatic acute HCV
No Reference
Yes 0.06 (−0.01, 0.13) 0.080
ALT level, log IU/L 0.07 (0.00, 0.14) 0.049 0.02 (−0.05, 0.10) 0.502
Estimated duration of infection
<26 weeks Reference
≥26 weeks −0.05 (−0.12, 0.02) 0.196
Interferon lambda rs12979860 genotype
TT/CT Reference
CC 0.01 (−0.06, 0.08) 0.809
HCV RNA level
<400,000 IU/mL Reference Reference
≥400,000 IU/mL 0.05 (−0.02, 0.12) 0.181 0.02 (−0.06, 0.10) 0.623
HCV genotypec
Genotype 1 Reference
Genotype 3 0.00 (−0.07, 0.08) 0.937
Other 0.09 (−0.05, 0.23) 0.222
aAdjusted for variables associated with MCP-1 levels in unadjusted analysis or HIV status (i.e. age, ALT levels, and HCV RNA levels) as well as assay run
(n = 117, R2 = 0.14)
bβ coefficient
cOverall P = 0.467
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the inflamed liver, as well as the activation of hepatic
stellate cells (HSC) which are key drivers of fibrosis
(reviewed in [24]). The role of CCR2 in promoting HSC
chemotaxis and the development of hepatic fibrosis has
been shown in animal models [25]. In humans, increased
MCP-1 expression and CCR2-dependent macrophage
infiltration in the liver [26, 27], and also higher MCP-1
plasma levels [28] have been found in the fibrotic liver.
An MCP-1 gene polymorphism has been associated with
increased expression of MCP-1 in the liver among indi-
viduals with chronic HCV and those with more ad-
vanced fibrosis [29]. In one longitudinal study, more
rapid progression of hepatic fibrosis in HCV infection
was correlated with persistent and significant elevation
of MCP-1 plasma levels from acute to chronic infection
[30]. Taken together, these data indicate the critical role
of MCP-1 in development and progression of liver fibro-
sis. This existing evidence, coupled with our findings of
increased MCP-1 plasma levels in HIV/HCV co-
infection suggest a potential explanation for accelerated
liver fibrosis progression in HIV/HCV co-infection,
compared to HCV mono-infection. This hypothesis is
supported by the in vitro data indicating that HIV can
infect activated hepatic stellate cells (HSCs) to induce
secretion of MCP-1 [31].
Knockout of CCR2 in mice results in reduced MCP-1
expression, diminished monocyte/macrophage infiltra-
tion and the development of lower levels of fibrosis fol-
lowing liver injury [32]. Further, data from animal
models indicate that inhibition of MCP-1 reduces intra-
hepatic macrophage accumulation and development of
steatohepatitis [21, 33]. Recently, Cenicriviric, a CCR2
and CCR5 antagonist, demonstrated good efficacy in
suppressing HIV in phase IIb clinical trials [34, 35]. In
addition to the antiretroviral effects, in animal models,
Cenicriviric is anti-fibrotic, and reduces liver fibrosis
progression [36]. One hypothesis is that the inhibition of
MCP-1 might have therapeutic potential in reducing
liver fibrosis progression in individuals with HIV/HCV
co-infection. This hypothesis is required to be supported
by further research to evaluate the potential effect of
inhibiting MCP-1 in reducing liver fibrosis.
Table 4 Unadjusted and adjusted models assessing the association of HIV co-infection with plasma eotaxin levels (log10 pg/mL) in
ATAHC
Unadjusted model Adjusted modela
Estimated mean differenceb (95 % CI) P Estimated mean differenceb (95 % CI) P
HIV co-infection
Negative Reference Reference
Positive 0.17 (0.07, 0.28) <0.001 0.12 (0.01, 0.24) 0.038
Age, 10 years 0.08 (0.03, 0.13) 0.001 0.06 (0.00, 0.12) 0.039
Symptomatic acute HCV
No Reference
Yes 0.05 (−0.05, 0.16) 0.309
ALT level, log IU/L 0.03 (−0.07, 0.14) 0.534 −0.02 (−0.13, 0.09) 0.712
Estimated duration of infection
<26 weeks Reference
≥26 weeks −0.05 (−0.15, 0.06) 0.375
Interferon lambda rs12979860 genotype
TT/CT Reference
CC 0.05 (−0.06, 0.15) 0.379
HCV RNA level
<400,000 IU/mL Reference Reference
≥400,000 IU/mL 0.01 (−0.10, 0.13) 0.791 −0.02 (−0.14, 0.09) 0.689
HCV genotypec
Genotype 1 Reference
Genotype 3 −0.08 (−0.19, 0.04) 0.184
Other 0.02 (−0.19, 0.23) 0.860
aAdjusted for variables associated with eotaxin levels in unadjusted analysis or HIV status (i.e. age, ALT levels, and HCV RNA levels) as well as assay run
(n = 117, R2 = 0.15)
b β coefficient
cOverall P = 0.372
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Individuals with HIV/HCV co-infection and recent
HCV infection in this study also demonstrated higher
plasma eotaxin levels compared to those with HCV
mono-infection. Eotaxin (CCL11) is a chemokine origin-
ally known as an eosinophil-specific chemoattractant
which regulates eosinophil trafficking and facilitates eo-
sinophil migration into the tissue by activating CCR3 re-
ceptors (reviewed in [37, 38]). Up-regulation of eotaxin
expression has been demonstrated in the liver of individ-
uals with drug-induced hepatitis and is accompanied by
liver infiltration of eosinophils [39]. In the setting of
HCV infection, increased plasma levels of eotaxin have
been demonstrated in individuals with chronic HCV in-
fection compared with healthy controls [40], while de-
velopment of persistent HCV has also been found to be
associated with higher plasma levels of eotaxin during
acute infection [41]. Moreover, eotaxin has a role in hep-
atic fibrogenesis. Higher plasma eotaxin levels have been
identified among individuals with liver cirrhosis, with
higher eotaxin levels associated with increasing stage of
fibrosis, and hepatic necro-inflammation and fibrosis by
liver histology [42]. The observation that higher eotaxin
plasma levels are observed in those with HIV/HCV co-
infection suggest that, similar to MCP-1, eotaxin might
have a role in explaining accelerated liver fibrosis in in-
dividuals with HIV/HCV co-infection.
This study had several limitations. First, this dataset
was cross-sectional, then it was not possible to measure
longitudinal levels of cytokines during acute HCV infec-
tion. Further, cytokine and chemokine concentrations
were measured from plasma samples, so it is possible
that the levels in the blood might not reflect hepatic
levels. However, it has been demonstrated that intrahe-
patic and peripheral sources of MCP-1 are known to
both contribute to elevated serum MCP-1 concentra-
tions [22]. Data on liver fibrosis levels was not available
in our participants. Further studies are needed to investi-
gate the role of high MCP-1 and eotaxin levels in liver
fibrosis progression among HIV/HCV co-infected indi-
viduals. Lastly, multiple comparison testing might inflate
type 1 error in data analysis. To account for this con-
cern, a moderately conservative significance level (alpha
= 0.01) was used. We also conducted a sensitivity ana-
lysis, using Bonferroni correction for multiple compari-
sons (alpha = 0.05/27 = 0.002) but the findings were
similar.
Conclusion
In conclusion, this study has demonstrated that com-
pared to those without HIV infection, following acute
HCV infection among people with HIV-infection, in-
creased levels of the pro-fibrogenic chemokines, MCP-1
and eotaxin were observed. These findings could suggest
a potential pathway possibly linking HIV infection with
liver fibrogenesis among people with HIV/HCV infec-
tion. These findings may have also potential implications
for therapeutic interventions to prevent liver fibrosis in
people with HIV/HCV co-infection.
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